Is TG Therapeutics Inc (TGTX) overvalued? · P/E 18, rev $240.3M
TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ.
This page asks whether TG Therapeutics Inc (TGTX) looks expensive on cached numbers — not a short thesis.
Latest reported TGTX revenue for 2026-06-30 was $240.3M. Net income was $7.8M. Revenue was up 17.3% from 2026-03-31 to 2026-06-30. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
TGTX currently screens at market cap $7.88B and trailing P/E 18.0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TGTX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TGTX stock page for the full model, not this heading.
Not investment advice.